BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 26014514)

  • 1. The Effects of PMM2-CDG-Causing Mutations on the Folding, Activity, and Stability of the PMM2 Protein.
    Yuste-Checa P; Gámez A; Brasil S; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
    Hum Mutat; 2015 Sep; 36(9):851-60. PubMed ID: 26014514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations.
    Vega AI; Pérez-Cerdá C; Abia D; Gámez A; Briones P; Artuch R; Desviat LR; Ugarte M; Pérez B
    J Inherit Metab Dis; 2011 Aug; 34(4):929-39. PubMed ID: 21541725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG.
    Yuste-Checa P; Brasil S; Gámez A; Underhaug J; Desviat LR; Ugarte M; Pérez-Cerdá C; Martinez A; Pérez B
    Hum Mutat; 2017 Feb; 38(2):160-168. PubMed ID: 27774737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteostasis regulators as potential rescuers of PMM2 activity.
    Vilas A; Yuste-Checa P; Gallego D; Desviat LR; Ugarte M; Pérez-Cerda C; Gámez A; Pérez B
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165777. PubMed ID: 32222543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2.
    Chan B; Clasquin M; Smolen GA; Histen G; Powe J; Chen Y; Lin Z; Lu C; Liu Y; Cang Y; Yan Z; Xia Y; Thompson R; Singleton C; Dorsch M; Silverman L; Su SM; Freeze HH; Jin S
    Hum Mol Genet; 2016 Jun; 25(11):2182-2193. PubMed ID: 27053713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Analysis of Variants in the General Population Reveals That
    Citro V; Cimmaruta C; Monticelli M; Riccio G; Hay Mele B; Cubellis MV; Andreotti G
    Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.
    Lao JP; DiPrimio N; Prangley M; Sam FS; Mast JD; Perlstein EO
    G3 (Bethesda); 2019 Feb; 9(2):413-423. PubMed ID: 30530630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients.
    Vuillaumier-Barrot S; Hetet G; Barnier A; Dupré T; Cuer M; de Lonlay P; Cormier-Daire V; Durand G; Grandchamp B; Seta N
    J Med Genet; 2000 Aug; 37(8):579-80. PubMed ID: 10922383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG).
    Thiesler CT; Cajic S; Hoffmann D; Thiel C; van Diepen L; Hennig R; Sgodda M; Weiβmann R; Reichl U; Steinemann D; Diekmann U; Huber NM; Oberbeck A; Cantz T; Kuss AW; Körner C; Schambach A; Rapp E; Buettner FF
    Mol Cell Proteomics; 2016 Apr; 15(4):1435-52. PubMed ID: 26785728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia.
    Westphal V; Peterson S; Patterson M; Tournay A; Blumenthal A; Treacy EP; Freeze HH
    Genet Med; 2001; 3(6):393-8. PubMed ID: 11715002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Congenital disorder of glycosylation type Ia (CDG Ia) - underdiagnosed entity?].
    Sätilä H; Kuusela AL; Pietilä K; Niinikoski H; Keskinen P
    Duodecim; 2016; 132(3):253-9. PubMed ID: 26951030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency.
    Westphal V; Kjaergaard S; Schollen E; Martens K; Grunewald S; Schwartz M; Matthijs G; Freeze HH
    Hum Mol Genet; 2002 Mar; 11(5):599-604. PubMed ID: 11875054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.
    Budhraja R; Radenkovic S; Jain A; Muffels IJJ; Ismaili MHA; Kozicz T; Pandey A; Morava E
    Mol Genet Metab; 2024 Jun; 142(2):108487. PubMed ID: 38733638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.
    Serrano M; de Diego V; Muchart J; Cuadras D; Felipe A; Macaya A; Velázquez R; Poo MP; Fons C; O'Callaghan MM; García-Cazorla A; Boix C; Robles B; Carratalá F; Girós M; Briones P; Gort L; Artuch R; Pérez-Cerdá C; Jaeken J; Pérez B; Pérez-Dueñas B
    Orphanet J Rare Dis; 2015 Oct; 10():138. PubMed ID: 26502900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and potential strategies for the treatment of PMM2-CDG.
    Gámez A; Serrano M; Gallego D; Vilas A; Pérez B
    Biochim Biophys Acta Gen Subj; 2020 Nov; 1864(11):129686. PubMed ID: 32712172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and molecular studies in 26 Spanish patients with congenital disorder of glycosylation type Ia.
    Briones P; Vilaseca MA; Schollen E; Ferrer I; Maties M; Busquets C; Artuch R; Gort L; Marco M; van Schaftingen E; Matthijs G; Jaeken J; Chabás A
    J Inherit Metab Dis; 2002 Dec; 25(8):635-46. PubMed ID: 12705494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PMM2-CDG: phenotype and genotype in four affected family members.
    Bortot B; Cosentini D; Faletra F; Biffi S; De Martino E; Carrozzi M; Severini GM
    Gene; 2013 Dec; 531(2):506-9. PubMed ID: 23988505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital disorder of glycosylation type Ia: searching for the origin of common mutations in PMM2.
    Quelhas D; Quental R; Vilarinho L; Amorim A; Azevedo L
    Ann Hum Genet; 2007 May; 71(Pt 3):348-53. PubMed ID: 17166182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypolipidaemia among patients with PMM2-CDG is associated with low circulating PCSK9 levels: a case report followed by observational and experimental studies.
    Chong M; Yoon G; Susan-Resiga D; Chamberland A; Cheillan D; Paré G; Seidah NG
    J Med Genet; 2020 Jan; 57(1):11-17. PubMed ID: 31391289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
    Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
    Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.